Logo image of AFX.DE

CARL ZEISS MEDITEC AG - BR (AFX.DE) Stock Fundamental Analysis

Europe - Frankfurt Stock Exchange - FRA:AFX - DE0005313704 - Common Stock

40.58 EUR
+0.58 (+1.45%)
Last: 12/12/2025, 7:00:00 PM
Fundamental Rating

5

Taking everything into account, AFX scores 5 out of 10 in our fundamental rating. AFX was compared to 64 industry peers in the Health Care Equipment & Supplies industry. AFX has an average financial health and profitability rating. AFX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

5

1. Profitability

1.1 Basic Checks

In the past year AFX was profitable.
In the past year AFX had a positive cash flow from operations.
Each year in the past 5 years AFX has been profitable.
Each year in the past 5 years AFX had a positive operating cash flow.
AFX.DE Yearly Net Income VS EBIT VS OCF VS FCFAFX.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

1.2 Ratios

Looking at the Return On Assets, with a value of 4.49%, AFX is in the better half of the industry, outperforming 60.32% of the companies in the same industry.
The Return On Equity of AFX (7.51%) is comparable to the rest of the industry.
AFX has a Return On Invested Capital (4.74%) which is in line with its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for AFX is in line with the industry average of 9.81%.
The 3 year average ROIC (9.30%) for AFX is well above the current ROIC(4.74%). The reason for the recent decline needs to be investigated.
Industry RankSector Rank
ROA 4.49%
ROE 7.51%
ROIC 4.74%
ROA(3y)8.42%
ROA(5y)8.24%
ROE(3y)12.26%
ROE(5y)11.91%
ROIC(3y)9.3%
ROIC(5y)9.86%
AFX.DE Yearly ROA, ROE, ROICAFX.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10

1.3 Margins

With a Profit Margin value of 7.19%, AFX perfoms like the industry average, outperforming 52.38% of the companies in the same industry.
In the last couple of years the Profit Margin of AFX has declined.
AFX has a Operating Margin (8.55%) which is in line with its industry peers.
In the last couple of years the Operating Margin of AFX has declined.
With a Gross Margin value of 52.43%, AFX perfoms like the industry average, outperforming 41.27% of the companies in the same industry.
AFX's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 8.55%
PM (TTM) 7.19%
GM 52.43%
OM growth 3Y-25.26%
OM growth 5Y-12.3%
PM growth 3Y-15.52%
PM growth 5Y-4.6%
GM growth 3Y-3.56%
GM growth 5Y-1.56%
AFX.DE Yearly Profit, Operating, Gross MarginsAFX.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

6

2. Health

2.1 Basic Checks

AFX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, AFX has less shares outstanding
The number of shares outstanding for AFX has been reduced compared to 5 years ago.
The debt/assets ratio for AFX is higher compared to a year ago.
AFX.DE Yearly Shares OutstandingAFX.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
AFX.DE Yearly Total Debt VS Total AssetsAFX.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B

2.2 Solvency

An Altman-Z score of 3.16 indicates that AFX is not in any danger for bankruptcy at the moment.
AFX's Altman-Z score of 3.16 is fine compared to the rest of the industry. AFX outperforms 65.08% of its industry peers.
AFX has a debt to FCF ratio of 7.17. This is a slightly negative value and a sign of low solvency as AFX would need 7.17 years to pay back of all of its debts.
The Debt to FCF ratio of AFX (7.17) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.27 indicates that AFX is not too dependend on debt financing.
AFX has a Debt to Equity ratio (0.27) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF 7.17
Altman-Z 3.16
ROIC/WACC0.7
WACC6.75%
AFX.DE Yearly LT Debt VS Equity VS FCFAFX.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B

2.3 Liquidity

AFX has a Current Ratio of 2.04. This indicates that AFX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.04, AFX is in the better half of the industry, outperforming 63.49% of the companies in the same industry.
A Quick Ratio of 1.17 indicates that AFX should not have too much problems paying its short term obligations.
AFX has a Quick ratio of 1.17. This is comparable to the rest of the industry: AFX outperforms 53.97% of its industry peers.
Industry RankSector Rank
Current Ratio 2.04
Quick Ratio 1.17
AFX.DE Yearly Current Assets VS Current LiabilitesAFX.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

4

3. Growth

3.1 Past

The earnings per share for AFX have decreased strongly by -25.00% in the last year.
Measured over the past 5 years, AFX shows a small growth in Earnings Per Share. The EPS has been growing by 2.35% on average per year.
Looking at the last year, AFX shows a small growth in Revenue. The Revenue has grown by 5.50% in the last year.
The Revenue has been growing slightly by 7.20% on average over the past years.
EPS 1Y (TTM)-25%
EPS 3Y-8.8%
EPS 5Y2.35%
EPS Q2Q%-15.79%
Revenue 1Y (TTM)5.5%
Revenue growth 3Y7.85%
Revenue growth 5Y7.2%
Sales Q2Q%1.92%

3.2 Future

AFX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.55% yearly.
The Revenue is expected to grow by 6.84% on average over the next years.
EPS Next Y-14.52%
EPS Next 2Y1.17%
EPS Next 3Y7.8%
EPS Next 5Y13.55%
Revenue Next Year6.32%
Revenue Next 2Y5.59%
Revenue Next 3Y6.13%
Revenue Next 5Y6.84%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
AFX.DE Yearly Revenue VS EstimatesAFX.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 500M 1B 1.5B 2B 2.5B
AFX.DE Yearly EPS VS EstimatesAFX.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1 2 3 4

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 23.73, which indicates a rather expensive current valuation of AFX.
Based on the Price/Earnings ratio, AFX is valued a bit cheaper than the industry average as 71.43% of the companies are valued more expensively.
The average S&P500 Price/Earnings ratio is at 26.54. AFX is around the same levels.
Based on the Price/Forward Earnings ratio of 19.73, the valuation of AFX can be described as rather expensive.
AFX's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. AFX is cheaper than 61.90% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.78. AFX is around the same levels.
Industry RankSector Rank
PE 23.73
Fwd PE 19.73
AFX.DE Price Earnings VS Forward Price EarningsAFX.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

AFX's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. AFX is cheaper than 73.02% of the companies in the same industry.
AFX's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 43.75
EV/EBITDA 12.08
AFX.DE Per share dataAFX.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)10.12
EPS Next 2Y1.17%
EPS Next 3Y7.8%

4

5. Dividend

5.1 Amount

AFX has a Yearly Dividend Yield of 1.38%.
Compared to an average industry Dividend Yield of 1.24, AFX pays a bit more dividend than its industry peers.
AFX's Dividend Yield is slightly below the S&P500 average, which is at 1.96.
Industry RankSector Rank
Dividend Yield 1.38%

5.2 History

The dividend of AFX is nicely growing with an annual growth rate of 15.07%!
Dividend Growth(5Y)15.07%
Div Incr Years1
Div Non Decr Years4
AFX.DE Yearly Dividends per shareAFX.DE Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

AFX pays out 33.69% of its income as dividend. This is a sustainable payout ratio.
AFX's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP33.69%
EPS Next 2Y1.17%
EPS Next 3Y7.8%
AFX.DE Yearly Income VS Free CF VS DividendAFX.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M 250M
AFX.DE Dividend Payout.AFX.DE Dividend Payout, showing the Payout Ratio.AFX.DE Dividend Payout.PayoutRetained Earnings

CARL ZEISS MEDITEC AG - BR

FRA:AFX (12/12/2025, 7:00:00 PM)

40.58

+0.58 (+1.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)12-11 2025-12-11/amc
Earnings (Next)02-10 2026-02-10
Inst Owners25.58%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.63B
Revenue(TTM)2.18B
Net Income(TTM)155.89M
Analysts73.64
Price Target55.56 (36.91%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.38%
Yearly Dividend1.11
Dividend Growth(5Y)15.07%
DP33.69%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.71%
Min EPS beat(2)-36.67%
Max EPS beat(2)13.25%
EPS beat(4)2
Avg EPS beat(4)-5.53%
Min EPS beat(4)-36.67%
Max EPS beat(4)37.18%
EPS beat(8)6
Avg EPS beat(8)8.89%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)2.29%
Min Revenue beat(2)0.82%
Max Revenue beat(2)3.76%
Revenue beat(4)3
Avg Revenue beat(4)0.58%
Min Revenue beat(4)-2.4%
Max Revenue beat(4)3.76%
Revenue beat(8)5
Avg Revenue beat(8)-0.67%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.39%
EPS NQ rev (1m)-4.88%
EPS NQ rev (3m)-4.88%
EPS NY rev (1m)-0.85%
EPS NY rev (3m)-4.94%
Revenue NQ rev (1m)-0.2%
Revenue NQ rev (3m)-0.2%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.31%
Valuation
Industry RankSector Rank
PE 23.73
Fwd PE 19.73
P/S 1.67
P/FCF 43.75
P/OCF 18.56
P/B 1.75
P/tB 9.36
EV/EBITDA 12.08
EPS(TTM)1.71
EY4.21%
EPS(NY)2.06
Fwd EY5.07%
FCF(TTM)0.93
FCFY2.29%
OCF(TTM)2.19
OCFY5.39%
SpS24.26
BVpS23.21
TBVpS4.34
PEG (NY)N/A
PEG (5Y)10.12
Graham Number29.88
Profitability
Industry RankSector Rank
ROA 4.49%
ROE 7.51%
ROCE 6.52%
ROIC 4.74%
ROICexc 4.83%
ROICexgc 12.2%
OM 8.55%
PM (TTM) 7.19%
GM 52.43%
FCFM 3.82%
ROA(3y)8.42%
ROA(5y)8.24%
ROE(3y)12.26%
ROE(5y)11.91%
ROIC(3y)9.3%
ROIC(5y)9.86%
ROICexc(3y)9.4%
ROICexc(5y)9.95%
ROICexgc(3y)15.11%
ROICexgc(5y)14.88%
ROCE(3y)12.78%
ROCE(5y)13.55%
ROICexgc growth 3Y-11.32%
ROICexgc growth 5Y-4.98%
ROICexc growth 3Y-28.53%
ROICexc growth 5Y-15.45%
OM growth 3Y-25.26%
OM growth 5Y-12.3%
PM growth 3Y-15.52%
PM growth 5Y-4.6%
GM growth 3Y-3.56%
GM growth 5Y-1.56%
F-Score4
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0.27
Debt/FCF 7.17
Debt/EBITDA 1.68
Cap/Depr 73.33%
Cap/Sales 5.19%
Interest Coverage 13.7
Cash Conversion 57.69%
Profit Quality 53.21%
Current Ratio 2.04
Quick Ratio 1.17
Altman-Z 3.16
F-Score4
WACC6.75%
ROIC/WACC0.7
Cap/Depr(3y)128.62%
Cap/Depr(5y)113.53%
Cap/Sales(3y)5.71%
Cap/Sales(5y)4.9%
Profit Quality(3y)45.51%
Profit Quality(5y)74.23%
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3Y-8.8%
EPS 5Y2.35%
EPS Q2Q%-15.79%
EPS Next Y-14.52%
EPS Next 2Y1.17%
EPS Next 3Y7.8%
EPS Next 5Y13.55%
Revenue 1Y (TTM)5.5%
Revenue growth 3Y7.85%
Revenue growth 5Y7.2%
Sales Q2Q%1.92%
Revenue Next Year6.32%
Revenue Next 2Y5.59%
Revenue Next 3Y6.13%
Revenue Next 5Y6.84%
EBIT growth 1Y-40.66%
EBIT growth 3Y-19.39%
EBIT growth 5Y-5.98%
EBIT Next Year56.91%
EBIT Next 3Y26.03%
EBIT Next 5Y19.93%
FCF growth 1Y-30.57%
FCF growth 3Y-31.55%
FCF growth 5Y-11.27%
OCF growth 1Y-1.41%
OCF growth 3Y-11.98%
OCF growth 5Y2.4%

CARL ZEISS MEDITEC AG - BR / AFX.DE FAQ

What is the fundamental rating for AFX stock?

ChartMill assigns a fundamental rating of 5 / 10 to AFX.DE.


Can you provide the valuation status for CARL ZEISS MEDITEC AG - BR?

ChartMill assigns a valuation rating of 3 / 10 to CARL ZEISS MEDITEC AG - BR (AFX.DE). This can be considered as Overvalued.


Can you provide the profitability details for CARL ZEISS MEDITEC AG - BR?

CARL ZEISS MEDITEC AG - BR (AFX.DE) has a profitability rating of 5 / 10.


What is the valuation of CARL ZEISS MEDITEC AG - BR based on its PE and PB ratios?

The Price/Earnings (PE) ratio for CARL ZEISS MEDITEC AG - BR (AFX.DE) is 23.73 and the Price/Book (PB) ratio is 1.75.


What is the financial health of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?

The financial health rating of CARL ZEISS MEDITEC AG - BR (AFX.DE) is 6 / 10.